Orchestra BioMed Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Orchestra BioMed Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue2.642.763.53-0.785.70
Cost of Revenue0.200.190.210.200.15
Gross Profit2.432.573.32-0.985.56
Operating Expenses
Research & Development42.8033.8221.9512.8913.48
Selling, General & Administrative23.9320.2614.037.9310.83
Operating Expenses66.7454.0835.9820.8224.31
Operating Income-64.30-51.51-32.66-21.80-18.75
Other Income/Expense
Interest Income3.365.250.050.000.33
Interest Expense-0.30-1.400.00-0.930.00
Other Income/Expense-0.08-0.29-1.000.70-0.18
Income
Income Before Tax-61.02-49.12-33.61-23.01-21.36
Income Tax Expense0.000.000.000.000.00
Net Income-61.02-49.12-33.61-23.01-21.36
Net Income - Continuous Operations-61.02-49.12-33.61-23.010.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-63.99-51.22-32.44-21.62-18.62
EBIT-64.30-51.51-32.66-21.80-18.75
Depreciation & Amortization0.310.290.220.180.14
Earnings Per Share
Basic EPS-2.00-1.00-1.00-11.00-11.00
Diluted EPS-2.00-1.00-1.00-11.00-11.00
Basic Shares Outstanding36.8233.2331.612.112.01
Diluted Shares Outstanding36.8233.2331.612.112.01